View Item 

Show simple item record

Is prostate cancer different in black men? Answers from 3 natural history models

dc.contributor.authorTsodikov, Alex
dc.contributor.authorGulati, Roman
dc.contributor.authorde Carvalho, Tiago M.
dc.contributor.authorHeijnsdijk, Eveline A. M.
dc.contributor.authorHunter‐merrill, Rachel A.
dc.contributor.authorMariotto, Angela B.
dc.contributor.authorde Koning, Harry J.
dc.contributor.authorEtzioni, Ruth
dc.date.accessioned2017-06-16T20:16:54Z
dc.date.available2018-08-07T15:51:23Zen
dc.date.issued2017-06-15
dc.identifier.citationTsodikov, Alex; Gulati, Roman; de Carvalho, Tiago M.; Heijnsdijk, Eveline A. M.; Hunter‐merrill, Rachel A. ; Mariotto, Angela B.; de Koning, Harry J.; Etzioni, Ruth (2017). "Is prostate cancer different in black men? Answers from 3 natural history models." Cancer 123(12): 2312-2319.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/137616
dc.publisherWiley Periodicals, Inc.
dc.subject.otherprostateâ specific antigen
dc.subject.otherracial disparities
dc.subject.othermass screening
dc.subject.otherstatistical methods and models
dc.subject.othercancer epidemiology
dc.subject.othernatural history
dc.subject.otherprostatic neoplasms
dc.titleIs prostate cancer different in black men? Answers from 3 natural history models
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137616/1/cncr30687.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137616/2/cncr30687_am.pdf
dc.identifier.doi10.1002/cncr.30687
dc.identifier.sourceCancer
dc.identifier.citedreferenceMariotto A, Etzioni R, Krapcho M, Feuer EJ. Reconstructing prostateâ specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007; 109: 1877 â 1886.
dc.identifier.citedreferenceSchwartz K, Powell IJ, Underwood W 3rd, George J, Yee C, Banerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology. 2009; 74: 1296 â 1302.
dc.identifier.citedreferenceGiovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997; 94: 3320 â 3323.
dc.identifier.citedreferenceBensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: a caseâ only study of 1,536 GWAS and candidate SNPs in Africanâ Americans and Europeanâ Americans. Prostate. 2013; 73: 1 â 22.
dc.identifier.citedreferenceFaisal FA, Sundi D, Tosoian JJ, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016; 70: 14 â 17.
dc.identifier.citedreferenceMoul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996; 155: 1667 â 1673.
dc.identifier.citedreferenceFaisal FA, Sundi D, Cooper JL, et al. Racial disparities in oncologic outcomes after radical prostatectomy: longâ term followâ up. Urology. 2014; 84: 1434 â 1441.
dc.identifier.citedreferenceBarocas DA, Gray DT, Fowke JH, et al. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012; 188: 1279 â 1285.
dc.identifier.citedreferenceShavers VL, Brown ML, Potosky AL, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004; 19: 146 â 155.
dc.identifier.citedreferenceKlabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36: 1337 â 1348.
dc.identifier.citedreferenceZeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEERâ Medicare trends 1991 to 1999. Urology. 2004; 64: 1171 â 1176.
dc.identifier.citedreferenceTaksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012; 118: 4280 â 4289.
dc.identifier.citedreferenceMetcalfe C, Evans S, Ibrahim F, et al. Pathways to diagnosis for black men and white men found to have prostate cancer: the PROCESS cohort study. Br J Cancer. 2008; 99: 1040 â 1045.
dc.identifier.citedreferencePowell IJ, Banerjee M, Sakr WA, et al. Should Africanâ American men be tested for prostate carcinoma at an earlier age than white men? Cancer. 1999; 85: 472 â 477.
dc.identifier.citedreferencePowell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prevent. 2014; 23: 1505 â 1511.
dc.identifier.citedreferenceGulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010; 11: 707 â 719.
dc.identifier.citedreferenceDraisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostateâ specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 68 â 878.
dc.identifier.citedreferenceTsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006; 25: 2846 â 2866.
dc.identifier.citedreferenceGulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostateâ specific antigenâ based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013; 158: 145 â 153.
dc.identifier.citedreferenceHeijnsdijk EA, de Carvalho TM, Auvinen A, et al. Costâ effectiveness of prostate cancer screening: a simulation study based on ERSPC data [serial online]. J Natl Cancer Inst. 2015; 107: 366.
dc.identifier.citedreferencevan Buuren S, Groothuisâ Oudshoorn K. Multivariate imputation by chained equations in R. J Stat Softw. 2011; 45: 1 â 67.
dc.identifier.citedreferenceEtzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008; 19: 175 â 181.
dc.identifier.citedreferenceEtzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012; 118: 5955 â 5963.
dc.identifier.citedreferencePowell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010; 183: 1792 â 1796.
dc.identifier.citedreferenceMoyer VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120 â 134.
dc.identifier.citedreferenceWolf AM. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60: 70 â 98.
dc.identifier.citedreferenceCarter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013; 190: 419 â 426.
dc.identifier.citedreferenceHall L, Bullock AD, Brown AL, Colditz G. Prostate cancer isn’t colorblind. New York Times. July 27, 2016: A27.
dc.identifier.citedreferenceGulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev. 2017; 26: 222 â 227.
dc.identifier.citedreferencePowell IJ. Epidemiology and pathophysiology of prostate cancer in Africanâ American men. J Urol. 2007; 177: 444 â 449.
dc.identifier.citedreferenceUnderwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004; 171: 1504 â 1507.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30687.pdf
Size:
389.5KB
Format:
PDF
View/Open
Name:
cncr30687_am.pdf
Size:
1.067MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.